publication . Review . 2010

The role of rasagiline in the treatment of Parkinson’s disease

Leegwater-Kim, Julie;
Open Access English
  • Published: 10 May 2010 Journal: Clinical Interventions in Aging (issn: 1178-1998, Copyright policy)
  • Publisher: Dove Press
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of onc...
free text keywords: Clinical Interventions in Aging
61 references, page 1 of 5

1. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525-35.

2. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55:259-272. [OpenAIRE]

3. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24: 197-211.

4. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889-909.

5. Olanow CW. Pathogenesis of cell death in Parkinson's disease. Mov Disord. 2007;22:S335-S342. [OpenAIRE]

6. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819-622.

7. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol. 2006;60: 389-398.

8. Klein C, Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol. 2007;20:453-464.

9. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281:341-346.

10. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006;354: 424-425.

11. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006;354:422-423.

12. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord. 2002;8:297-309.

13. Vogel WH, Orfei V, Century B. Activities of enzymes involved in the formation and destruction of biogenic amines in various areas of human brain. J Pharmacol Exp Ther. 1969;165:196-203.

14. Tallman JF, Saavedra JM, Axelrod J. Biosynthesis and metabolism of endogenous tyramine and its normal presence in sympathetic nerves. J Pharmacol Exp Ther. 1976:199:216-221.

15. Collins GG, Sandler M, Williams ED, Youdim MB. Multiple forms of human brain monoamine oxidase. Nature. 1970;225:817-820. [OpenAIRE]

61 references, page 1 of 5
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue